Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
P 1 (2)
P 2 (3)

Trial Status

Recruiting2
Withdrawn1
Unknown1
Active Not Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06102902Phase 1Suspended

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

NCT07147231Phase 1Recruiting

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

NCT03087071Phase 2Active Not Recruiting

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

NCT06171854Phase 2UnknownPrimary

caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

NCT04119830Phase 2Withdrawn

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Showing all 5 trials

Research Network

Activity Timeline